Related Experiment Videos
CA-125 concentrations in malignant and nonmalignant disease
1Department of Pathology, Washington University School of Medicine, St. Louis, MO 63110.
Clinical Chemistry
|November 1, 1991
Summary
CA-125 is a tumor marker useful for monitoring ovarian cancer treatment and recurrence. However, elevated levels in benign conditions limit its use for screening or differentiating malignant from non-malignant diseases.
Area of Science:
- Oncology
- Biochemistry
Background:
- CA-125 is a glycoprotein found on cancer cells, often used in ovarian cancer monitoring.
- It has been explored as a noninvasive biomarker to distinguish benign from malignant conditions.
Observation:
- CA-125 monitoring is effective for tracking ovarian carcinoma treatment response and detecting recurrence.
- Elevated CA-125 levels are frequently observed in various benign conditions, including menstruation, pregnancy, and pelvic inflammatory diseases.
Findings:
- Despite its utility in monitoring, CA-125 has limited value as a screening test for ovarian cancer due to high false-positive rates.
- Significant increases in CA-125 (up to 5000 units/mL) can occur in benign conditions, complicating its diagnostic specificity.
- While very high levels are occasionally seen in ovarian cancer, no specific concentration definitively diagnoses malignancy.
Implications:
- CA-125 is a valuable tool for monitoring existing ovarian cancer but not for initial screening or definitive diagnosis.
- Further research may be needed to identify more specific biomarkers for early ovarian cancer detection.
- Understanding the limitations of CA-125 in benign conditions is crucial for accurate patient management.